Preface [Hot Topic: Peptides and Peptidomimetics as Anti-Cancer Therapeutics (Executive Editor: Nadya I. Tarasova)]
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
iii-iii
Author(s):
Nadya I. Tarasova
Membrane Disrupting Lytic Peptides for Cancer Treatments
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2299-2310
Author(s):
Carola Leuschner and William Hansel
Small Molecule Toxins Targeting Tumor Receptors
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2311-2334
Author(s):
Marcin Dyba, Nadya I. Tarasova and Christopher J. Michejda
Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2335-2343
Author(s):
T. Mori
Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2345-2358
Author(s):
William Rengifo-Cam and Pomila Singh
The Urokinase Receptor as a Potential Target in Cancer Therapy
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2359-2376
Author(s):
John Romer, Boye Schnack Nielsen and Michael Ploug
An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2377-2389
Author(s):
O.M. Zack Howard and Carole L. Galligan
Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Journal:
Current Drug Delivery
Volume:
1
Page:
203-212
Author(s):
V. Merino, N. V. Jiménez-Torres and M. Merino-Sanjuan
First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase
Journal:
Letters in Drug Design & Discovery
Volume:
1
Page:
194-197
Author(s):
E. Bellavance, V. Luu-The and D. Poirier
Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Journal:
Letters in Drug Design & Discovery
Volume:
1
Page:
247-255
Author(s):
P. S. Cogan, C. R. Fowler, G. C. Post and T. H. Koch